SCHEMBL5229260

SCHEMBL5229260

CSc1nc2c(c(-c3ccccc3)n1)C(=O)N(Cc1cc(C(F)(F)F)cc(C(F)(F)F)c1)CCCN2

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TACR1 P25103 13/20 0.41
ALDH1A1 P00352 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
KDM4E B2RXH2 1/20 0.36
HPGD P15428 1/20 0.36
PSEN1 P49768 1/20 0.35
PSEN2 P49810 1/20 0.35
APH1B Q8WW43 1/20 0.35
NCSTN Q92542 1/20 0.35
APH1A Q96BI3 1/20 0.35
PSENEN Q9NZ42 1/20 0.35
CYP3A4 P08684 2/20 0.33
ROCK2 O75116 1/20 0.33
ROCK1 Q13464 1/20 0.33
ADRB2 P07550 1/20 0.33
FPR1 P21462 1/20 0.33
GPR183 P32249 1/20 0.33
APLNR P35414 1/20 0.33
GLP1R P43220 1/20 0.33
GPBAR1 Q8TDU6 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5228468 0.92 TACR1 (0.41) TACR1ALDH1A1PSEN1PSEN2APH1B
SCHEMBL5230402 0.89 TACR1 (0.40) TACR1PSEN1PSEN2APH1BNCSTN
SCHEMBL5236630 0.87 TACR1 (0.37) TACR1ALDH1A1KDM4EHPGDPSEN1
SCHEMBL5228204 0.86 TACR1 (0.41) TACR1ALDH1A1SMN1; SMN2HPGDPSEN1
SCHEMBL5226634 0.85 TACR1 (0.38) TACR1ALDH1A1SMN1; SMN2PSEN1PSEN2
SCHEMBL5230109 0.84 TACR1 (0.39) TACR1PSEN1PSEN2APH1BNCSTN
SCHEMBL14433957 0.84 TACR1 (0.37) TACR1SMN1; SMN2PSEN1PSEN2APH1B
SCHEMBL13891713 0.83 TACR1 (0.42) TACR1ROCK2ROCK1ADRB2FPR1
SCHEMBL5232522 0.82 MET (0.40) TACR1HPGDCYP3A4CYP2D6USP2
SCHEMBL5230152 0.81 TACR1 (0.37) TACR1PSEN1PSEN2APH1BNCSTN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1496059-B1 FUSED BICYCLIC PYRIMIDINE DERIVATIVES KYORIN SEIYAKU KK (JP) 2007-08-15 EP disclosed
EP-1496059-B1 FUSED BICYCLIC PYRIMIDINE DERIVATIVES KYORIN SEIYAKU KK (JP) 2007-08-15 EP disclosed
US-7064119-B2 Fused bicyclic pyrimidine derivatives KYORIN PHARMACEUTICAL CO., LTD. (JP) 2006-06-20 US disclosed
US-20050159409-A1 Fused bicyclic pyrimidine derivatives KYORIN PHARMACEUTICAL CO. LTD. (JP) 2005-07-21 US disclosed
EP-1496059-A1 FUSED BICYCLIC PYRIMIDINE DERIVATIVES Kyorin Pharmaceutical Co., Ltd. (JP) 2005-01-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050159409-A1 Fused bicyclic pyrimidine derivatives BDKRB1, BDKRB2, TACR1 TACR1 3/4885ALDH1A1 1993/4885SMN1; SMN2 4586/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.